Investigational drug · Phase 2
MBF-015
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Huntington Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 3, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
2
Any phase or sponsor naming "MBF-015"
First trial start
2024
Feb 1, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MBF-015", any sponsor or status.
Conditions studied
As listed on its trial records.
- Huntington Disease
Approved drugs for the same conditions: Huntington's disease chorea · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "MBF-015" as an intervention, largest first.
Medibiofarma S.L.Industry
NCT06049147 · 72 participants · Start Jul 7, 2021 · Primary completion Aug 24, 2023
Drug: MBF-015 4 mg oral capsule; MBF-015 16 mg oral capsule and 1 more · For: Safety and Pharmacokinetic
Sites: Barcelona, Spain
Medibiofarma S.L.Industry
NCT06469853 · 10 participants · Start Feb 1, 2024 · Primary completion Dec 4, 2024
Drug: MBF-015 16 mg oral capsules · For: Huntington Disease
Sites: Barcelona, Spain
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Huntington Disease
- SKY-0515Phase 33 trials
Skyhawk Therapeutics, Inc. · Huntington Disease, Huntingtons Disease, Huntington's Disease (HD)
- PridopidinePhase 32 trials
Prilenia · Amyotrophic Lateral Sclerosis, Huntington Disease
- ER2001Phase 21 trial
ExoRNA Bioscience · Huntington Disease
- TominersenRO7234292, RG6042Phase 21 trial
Roche (Genentech) · Huntington Disease
- VO659Phase 21 trial
Vico Therapeutics B. V. · Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 3, Huntington Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.